SCHEMBL8202367

SCHEMBL8202367

CCCOc1cccc(-c2cc(-c3ccc(C4=NCCN4)cc3)no2)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.53
MAOA P21397 3/20 0.53
NISCH Q9Y2I1 4/20 0.48
CXCR1 P25024 4/20 0.47
CYP1A2 P05177 3/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP19A1 P11511 1/20 0.45
S1PR1 P21453 2/20 0.45
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8197632 0.89 CXCR1 (0.51) MAOBNISCHCXCR1CYP1A2CYP2C9
SCHEMBL8202987 0.86 MAOB (0.69) MAOBMAOANISCHCYP1A2CYP2C9
SCHEMBL8196068 0.85 MAOB (0.55) MAOBMAOANISCHCXCR1CYP1A2
SCHEMBL1796041 0.82 NISCH (0.56) MAOBMAOANISCHCYP1A2ALDH1A1
Hydrochloric Acid SCHEMBL1796884 0.81 NISCH (0.55) MAOBMAOANISCHCYP1A2ALDH1A1
SCHEMBL8214278 0.79 ALDH1A1 (0.65) MAOBMAOANISCHCYP1A2ALDH1A1
SCHEMBL1794747 0.78 TOP2A (0.61) MAOBMAOANISCHCYP1A2ALDH1A1
SCHEMBL8215584 0.78 HSD17B1 (0.65) MAOBMAOANISCHCYP1A2ALDH1A1
SCHEMBL1795198 0.78 NISCH (0.56) MAOBMAOANISCHCYP1A2ALDH1A1
SCHEMBL1795751 0.77 NISCH (0.59) MAOBMAOANISCHCYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2000078726-A1 IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES ELI LILLY AND COMPANY (US) 2000-12-28 WO disclosed